October 2022
Volume 11, Issue 10
Open Access
Erratum  |   October 2022
Erratum in: SZN-413, a FZD4 Agonist, as a Potential Novel Therapeutic for the Treatment of Diabetic Retinopathy
Translational Vision Science & Technology October 2022, Vol.11, 31. doi:https://doi.org/10.1167/tvst.11.10.31
  • Views
  • PDF
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Erratum in: SZN-413, a FZD4 Agonist, as a Potential Novel Therapeutic for the Treatment of Diabetic Retinopathy. Trans. Vis. Sci. Tech. 2022;11(10):31. doi: https://doi.org/10.1167/tvst.11.10.31.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Erratum in: “SZN-413, a FZD4 Agonist, as a Potential Novel Therapeutic for the Treatment of Diabetic Retinopathy” by Huy Nguyen, Hui Chen, Meghah Vuppalapaty, Elizabeth Whisler, Kelsey Ronarda Logas, Parthasarathy Sampathkumar, Russell Byron Fletcher, Asmiti Sura, Nicholas Suen, Suhani Gupta, Tom Lopez, Jay Ye, Shengjiang Tu, Menaka Bolaki, Wen-Chen Yeh, Yang Li, and Sung-Jin Lee (Transl Vis Sci Technol. 2022;11(9):19), https://doi.org/10.1167/tvst.11.9.19
Due to publisher error, the Disclosure in the Acknowledgments was incomplete when the article was first published. The Disclosure has now been updated in the article online. 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×